• GSK held its third-quarter 2026 results call October 28, attended by CEO Luke Miels, CFO Julie Brown, Tony Wood and Nina Mojas.
• Sales rose 5% to £8.9 billion at constant exchange rates; core operating profit increased 5%.
• Management reaffirmed full-year guidance, expecting sales and core operating profit in the upper half of their ranges.
• Restructuring charges could reach £1 billion this year; Brown indicated 2027 interest costs of £900 million to £1 billion.
• Four-monthly HIV prevention data remain under analysis, with regulatory submission expected before year-end; management maintained there was no read-through to treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.